Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with or without tremelimumab in MSS and MSI colorectal and endometrial tumors
2021-004061-13Phase 2Active
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- Mar 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab and tremelimumab in colorectal cancer (CRC) and endometrial cancer (EC) (4 arms), sponsored by Vall d'Hebron Institute of Oncology. Primary endpoint: Objective response rate. Started Mar 2022; status: active.
02
Drugs
durvalumabtremelimumab
03
Conditions
colorectal cancer (CRC)endometrial cancer (EC)
Beyond the preview
Go deeper on 2021-004061-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004061-13.